GLPwatch
Bydureon vs Wegovy
Drug comparison
Last updated 2026-05-28 15:46 UTCBydureon (exenatide by AstraZeneca) is a once-weekly injection for type 2 diabetes, while Wegovy (semaglutide by Novo Nordisk) is a once-weekly injection approved for obesity and reducing cardiovascular risk. Both are given under the skin, but Bydureon uses exenatide while Wegovy uses semaglutide.
AI summary of the sources below.
| Bydureon | Wegovy | |
|---|---|---|
| Active ingredient | exenatide | semaglutide |
| Manufacturer | astrazeneca | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | obesity, cardiovascular risk reduction |
| Label updated | — | 2026-05-05 |